
Your evidence rules out architecture hunting as the primary path:

- Majority-collapse fields have insufficient class variation. No model can learn a class that is nearly absent.
- Numeric fields are limited by label resolution and annotator noise. A 0.93 µm MAE on a 1 µm grid is already near the annotation floor.
- Loop length fails even with human boxes. That is an oracle result against the detector being the main bottleneck.
- Malformation performance is capped by both omitted abnormal-vessel annotations and only moderate human-box AUROC.
- Archive dependence means some apparent signal is acquisition-specific.
- Uncalibrated pixels cannot support absolute micron claims.

I would rule **in**:

- Label redesign: merge clinically indistinguishable bins, define abstention/“not assessable,” and remove fields with no usable prevalence.
- Independent double annotation with adjudication and inter-rater statistics.
- Explicit abnormal-vessel annotation, including hard negatives.
- Device-specific calibration and prospective acquisition metadata.
- A constrained model only after the labels are repaired: calibrated per-field classifiers, ordinal/regression models where justified, and detector-free image-quality gating.

I would rule **out**:

- More backbones, LoRA ranks, unfreezing, loss tricks, temporal input, PCA variants, or geometric features as the main rescue.
- Treating the detector’s mAP as evidence of clinical usefulness.
- Using transfer learning to compensate for missing or contradictory labels.
- Reporting the locked test repeatedly. Its budget is already spent.

Your reasoning error would be **capacity fixation**: continuing to search model space after oracle and label-granularity experiments have identified the ceiling.

2. **Your ruler is directionally right but statistically incomplete.**

For a consumer health product, requiring improvement over majority baseline is appropriate. Requiring leave-one-archive-out stability is also appropriate because archive shift is demonstrably real.

What is too crude is making “bootstrap CI excludes zero” the sole gate. With 186 cases, that criterion confounds usefulness with sample size and ignores asymmetric harm. Replace it with a prespecified gate containing:

- Cross-archive performance.
- A clinically or operationally meaningful minimum effect, not merely positive significance.
- Confidence intervals for sensitivity, specificity, calibration, and abstention rate.
- A locked prospective or temporally separated validation set.
- Per-subgroup and per-device reporting.
- A clear “insufficient image quality” behavior.

Do **not** relax:

- Independent validation.
- Archive/device robustness.
- Predefined acceptance thresholds.
- Honest abstention.
- Separation of image-quality outputs from physiological findings.
- The ban on disease claims without independent patient labels.

Your user’s “this makes delivery impossible” argument is not evidence that the ruler is too strict. It may mean the proposed product claims exceed what the dataset can support.

3. **A two-field product can be legitimate, but only with narrow positioning.**

It is legitimate if the output is explicitly:

- “Image clarity: usable/not usable”
- “Exudation observed/not observed,” with defined uncertainty and abstention

It becomes self-deception if marketed as a general microcirculation or vascular-health monitor. Two surviving fields do not validate the other 19, nor do they establish clinical utility.

Clarity being an image-quality field makes it **better as a safety/control feature and worse as a headline health feature**. It can prevent users from trusting unusable images and can gate downstream analysis. It is not evidence of physiological status.

Exudation is more product-relevant, but only if its label definition is reproducible, archive-invariant, and not merely a reader’s stylistic impression.

4. **Retinal-vessel transfer learning will not fix the stated failure.**

It might improve low-level vessel representations or initialization. It will not solve omitted abnormal-vessel annotations, sign-reversed correlations, archive confounding, or poor label definitions.

The relevant transfer is not “use a better vessel backbone.” It is:

- annotate abnormal vessels explicitly;
- retrain and audit the detector on those annotations;
- evaluate recall by abnormality type;
- use human-box performance as the ceiling;
- test whether improved annotations change downstream crossing/malformation validity.

Without that, transfer learning risks producing a more confident model trained against the same wrong target.

5. **Highest-value next action: rebuild the supervision and validation substrate before touching architecture.**

Run a prospective, device-documented, independently collected annotation study with:

- patient-linked metadata and independently established clinical labels where claims require them;
- calibrated acquisition metadata: device, magnification, pixel scale, preprocessing;
- explicit field definitions and “not assessable” states;
- double annotation plus adjudication;
- complete abnormal-vessel annotations;
- a new locked validation cohort from new acquisitions.

Until that exists, stop architecture experimentation. The external datasets you audited are not independent validation sets: one is an extension/equipment confound, and the other lacks usable labels. Treating either as disease-validation evidence would be a serious dataset reasoning error.

[exited with code 0]
